Pathophysiology and treatment of pulmonary hypertension in sickle cell disease
Open Access
- 18 February 2016
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 127 (7), 820-828
- https://doi.org/10.1182/blood-2015-08-618561
Abstract
Pulmonary hypertension affects ∼10% of adult patients with sickle cell disease (SCD), particularly those with the homozygous genotype. An increase in pulmonary artery systolic pressure, estimated noninvasively by echocardiography, helps identify SCD patients at risk for pulmonary hypertension, but definitive diagnosis requires right-heart catheterization. About half of SCD-related pulmonary hypertension patients have precapillary pulmonary hypertension with potential etiologies of (1) a nitric oxide deficiency state and vasculopathy consequent to intravascular hemolysis, (2) chronic pulmonary thromboembolism, or (3) upregulated hypoxic responses secondary to anemia, low O2 saturation, and microvascular obstruction. The remainder have postcapillary pulmonary hypertension secondary to left ventricular dysfunction. Although the pulmonary artery pressure in SCD patients with pulmonary hypertension is only moderately elevated, they have a markedly higher risk of death than patients without pulmonary hypertension. Guidelines for diagnosis and management of SCD-related pulmonary hypertension were published recently by the American Thoracic Society. Management of adults with sickle-related pulmonary hypertension is based on anticoagulation for those with thromboembolism; oxygen therapy for those with low oxygen saturation; treatment of left ventricular failure in those with postcapillary pulmonary hypertension; and hydroxyurea or transfusions to raise the hemoglobin concentration, reduce hemolysis, and prevent vaso-occlusive events that cause additional increases in pulmonary pressure. Randomized trials have not identified drugs to lower pulmonary pressure in SCD patients with precapillary pulmonary hypertension. Patients with hemodynamics of pulmonary arterial hypertension should be referred to specialized centers and considered for treatments known to be effective in other forms of pulmonary arterial hypertension. There have been reports that some of these treatments improve SCD-related pulmonary hypertension.This publication has 89 references indexed in Scilit:
- Mortality in Adults With Sickle Cell Disease and Pulmonary HypertensionJAMA, 2012
- Hypoxia-Inducible Factors in Physiology and MedicineCell, 2012
- Plexiform Lesions in Pulmonary Arterial Hypertension: Composition, Architecture, and MicroenvironmentThe American Journal of Pathology, 2011
- The AdventitiaArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell diseaseBritish Journal of Haematology, 2009
- Emerging concepts in acute mountain sickness and high-altitude cerebral edema: from the molecular to the morphologicalCellular and Molecular Life Sciences, 2009
- JNK signaling in apoptosisOncogene, 2008
- Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell diseaseAmerican Journal of Hematology, 2007
- Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell DiseaseJournal of the American College of Cardiology, 2007
- Severity of pulmonary hypertension during vaso‐occlusive pain crisis and exercise in patients with sickle cell diseaseBritish Journal of Haematology, 2006